FDA Continues Its Singulair Side-Effect Study

More than 10 months after the FDA began studying whether Merck’s allergy and asthma drug Singulair had mood and behavioral side effects, the agency reports that no conclusion has been reached. “FDA is continuing to review clinical trial data to assess other neuropsychiatric events, (mood and behavioral adverse events) related to drugs that act through the leukotriene pathway,” the agency says in a MedWatch report issued last week.
Washington Drug Letter